Briefing
A Study of Retifanlimab After Chemoradiation in People With Anal Cancer
NCT07927998 (PACER) is a recruiting, single-arm phase 2 MSK trial (estimated enrollment 25) of retifanlimab after definitive chemoradiation in people with anal squamous cell carcinoma who remain Signatera-positive, with the rate of ctDNA clearance at 12 weeks as the primary endpoint.